Viewing nowCombinationAmolbika Tablets 10/40mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.

MFDS item code 201404736 · Approved 2014.10.15 · Insurance code 649102480
Treatment of essential hypertension not controlled with monotherapy
If your blood pressure is not adequately controlled using Amlodipine or Olmesartan Medoxomil as monotherapy, these agents can be used to effectively manage blood pressure in the treatment of essential hypertension. These drugs help maintain blood pressure within the normal range by either dilating blood vessels or lowering blood pressure. Therefore, these drugs are used in the treatment of essential hypertension.
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60 mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not be administered this medicine, under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
○ Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to individuals with allergies to this drug's main ingredients or similar substances, pregnant or lactating women, patients with severe liver impairment or aortic stenosis, patients with biliary obstruction, patients undergoing dialysis, patients in shock, and certain diabetic patients. Careful monitoring of the patient's condition is required upon initial use in hypotensive patients with fluid or sodium depletion, as low blood pressure may occur. Patients with aortic stenosis should be particularly cautious as blood vessels may dilate and cause acute hypotension. Patients with severe obstructive coronary artery disease may experience an increased risk of angina or myocardial infarction when using this drug. Patients with heart failure should use this drug with caution, and those with impaired kidney function should closely monitor kidney function during treatment. Patients with liver dysfunction should be cautious as this drug is metabolized in the liver. During treatment, side effects such as dizziness, headaches, hypotension, nausea, edema, etc. may occur, and rare cases of serious allergic reactions or liver function abnormalities may also arise. Particularly during pregnancy, the drug may be hazardous to the fetus, and lactating women should either discontinue breastfeeding or stop taking the drug. Safety and efficacy in children under 18 years have not been established, and its use in this population is not recommended. Elderly individuals may have impaired liver, kidney, or heart function, so starting dosage should be low, with close monitoring of their condition. In the event of an overdose, hypotension and cardiac function impairment may occur, requiring immediate medical attention. This drug should be stored away from direct sunlight and moisture, and out of reach of children. Additionally, there may be interactions with other medications, so patients must inform their doctors or pharmacists and seek consultation.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress, ideally at room temperature between 1 to 30 degrees Celsius. Proper temperature and storage methods are essential to maintain the drug's effectiveness and ensure safe use.
Brownish-red round film-coated tablet
30 tablets (10 tablets in PTP packaging x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.